Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer.
Journal Information
Full Title: Appl Immunohistochem Mol Morphol
Abbreviation: Appl Immunohistochem Mol Morphol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Histocytochemistry
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"M.K. reports receiving lecture fees from Agilent Technologies and has no additional potential conflicts of interest to disclose. E.D.-K. served on an oncology advisory board for Eli Lilly and Company. F.S. is an employee and company stockholder at Eli Lilly and Company. S.R.W. is an employee and company stockholder at Eli Lilly and Company. A.M.G. is an employee and company stockholder at Eli Lilly and Company; he also reports his spouse is an employee of Eli Lilly and Company. S.S.B. has received grant or research support from Agilent Technologies and is a paid speaker for Agilent Technologies."
"This work was supported by Eli Lilly and Company."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025